Results 21 to 30 of about 78,685 (264)

The Chimeric Antigen Receptor Detection Toolkit [PDF]

open access: yesFrontiers in Immunology, 2020
Chimeric antigen receptor-T (CAR-T) cell therapy is a promising frontier of immunoengineering and cancer immunotherapy. Methods that detect, quantify, track, and visualize the CAR, have catalyzed the rapid advancement of CAR-T cell therapy from preclinical models to clinical adoption.
Yifei Hu, Yifei Hu, Jun Huang
openaire   +3 more sources

Chimeric Antigen Receptor Therapy for Cancer [PDF]

open access: yesAnnual Review of Medicine, 2014
Improved outcomes for patients with cancer hinge on the development of new targeted therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical, and clinical arenas spanning cellular immunology, synthetic biology, and cell-processing technologies has paved the way for clinical applications of chimeric antigen receptor ...
David M, Barrett   +4 more
openaire   +2 more sources

Posttransplant chimeric antigen receptor therapy [PDF]

open access: yesBlood, 2018
Abstract Therapeutic T-cell engineering is emerging as a powerful approach to treat refractory hematological malignancies. Its most successful embodiment to date is based on the use of second-generation chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule found in most B-cell leukemias and lymphomas.
Melody Smith   +3 more
openaire   +2 more sources

Generation of Chimeric Antigen Receptors against Tetraspanin 7

open access: yesCells, 2023
Adoptive transfer of antigen-specific regulatory T cells (Tregs) has shown promising results in the treatment of autoimmune diseases; however, the use of polyspecific Tregs has limited effects.
Tom Pieper   +10 more
doaj   +1 more source

Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis

open access: yesNature Communications, 2022
Co-expression of PD-L1-specific chimeric switch receptors (CSRs) improves the antitumor effects of chimeric antigen receptor (CAR) T cells. Here, CSRs are shown to promote the differentiation of mesothelin-targeting CAR T cells into central memory-like ...
Le Qin   +23 more
doaj   +1 more source

A TCR-based Chimeric Antigen Receptor [PDF]

open access: yesScientific Reports, 2017
AbstractEffector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection. Although very potent, CAR recognition is limited to membrane antigens which represent around 1% of the total proteins ...
Even Walseng   +8 more
openaire   +3 more sources

An Interesting Similarity of Bacillus Calmette-Guerin and Chimeric Antigen Receptor T Cells

open access: yesTranslational Research in Urology, 2020
Intravesical Bacillus Calmette-Guerin (BCG) is approved for non-muscle invasive bladder cancer treatment a long time ago. Chimeric antigen receptor T cells (CAR-Tcell), are T cells are genetically engineered T cells that produce an artificial T-cell ...
Seyed Saeed Tamehri Zadeh   +1 more
doaj   +1 more source

CAR-T cell therapy for hematological malignancies: History, status and promise

open access: yesHeliyon, 2023
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis.
Chao Wang   +3 more
doaj   +1 more source

[Chimeric antigen receptor T cells].

open access: yesBulletin du cancer, 2021
Chimeric antigen receptor T-cell (CAR T-cells) therapies which are genetically modified T lymphocyte targeting tumor antigens have modified therapeutic landscape in hematology. Aggressive B cells lymphoma are currently treated in daily practice with anti-CD19 CAR T.
Bories, Pierre, Ysebaert, Loïc
openaire   +2 more sources

Chimeric Antigen Receptor Therapy

open access: yesNew England Journal of Medicine, 2018
Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors.
Carl H. June, Michel Sadelain
openaire   +3 more sources

Home - About - Disclaimer - Privacy